Overview of Campto

Quick Facts

Property	Description
Active Ingredient	Irinotecan Hydrochloride Trihydrate
Form	Concentrate for solution for infusion
Pharmacological Class	Antineoplastic Agent / Topoisomerase I Inhibitor
General Purpose	To disrupt the growth of rapidly dividing, abnormal cells
Origin	Semisynthetic (Camptothecin derivative)

1. What Type of Medicine is Campto (Irinotecan)?

Campto is a powerful prescription-only medicine classified as an antineoplastic agent, a specialized category of chemotherapy used to manage abnormal, rapidly dividing cells. Its active ingredient is Irinotecan Hydrochloride Trihydrate, which functions specifically as a Topoisomerase I Inhibitor. Irinotecan is categorized within the group of antineoplastic agents, reflecting its specialized role in treating cellular proliferation. The medication’s classification as a focused systemic tool is clinically recognized across major oncology protocols. Irinotecan is also broadly categorized as a cytotoxic agent, meaning it works by directly interfering with and harming targeted cells. This classification is based on its precise molecular action, which is distinct from hormonal therapies or immunotherapies. The medicine is exclusively intended for parenteral administration via intravenous infusion, a method required due to its systemic nature and specialized formulation.

2. Composition, Form, and Origin of Irinotecan

The active substance, Irinotecan Hydrochloride Trihydrate, is supplied as a concentrate for solution for infusion, delivered in an aqueous solution (a water-based liquid vehicle). Irinotecan is a semisynthetic compound, meaning its structure is chemically manufactured using a base molecule derived from the natural alkaloid, camptothecin. Irinotecan is a camptothecin derivative with recognized antitumor activity. The efficacy of this semisynthetic structure is clinically established for use in medical settings. This final dosage form—a sterile concentrate—is designed to be diluted prior to use, facilitating precise, controlled administration directly into the bloodstream. This formulation ensures rapid and controlled systemic delivery, a key factor distinguishing it from oral chemotherapy agents.

3. General Purpose of this Cytotoxic Agent

The general purpose of the Irinotecan cytotoxic agent is to halt the uncontrolled proliferation of abnormal cells by interfering with their ability to replicate their genetic material. This action leverages the drug's role as a Topoisomerase I Inhibitor, which blocks a critical enzyme necessary for maintaining the integrity of DNA during cell division.

By specifically causing damage to the DNA of fast-dividing cells, Irinotecan forces these abnormal cells to stop reproducing and ultimately triggers a process of self-destruction. This focused intervention at the cellular level is the core benefit of the medication, establishing its role as a powerful systemic tool in managing conditions characterized by rapid cell growth.

What side effects are possible with Campto?

Campto (irinotecan) is associated with several serious and common adverse reactions, primarily affecting the gastrointestinal and hematological systems, which may necessitate dose adjustments or treatment delays.

Serious and Clinically Significant Reactions

Severe Diarrhea: This is a major dose-limiting toxicity. It is classified into two types: early-onset diarrhea (within 24 hours of infusion), often accompanied by cholinergic symptoms like rhinitis, sweating, and lacrimation, and late-onset diarrhea (typically >24 hours post-infusion). Late-onset diarrhea can be life-threatening due to potential dehydration, electrolyte imbalance, or sepsis.
Myelosuppression: Severe bone marrow suppression, most notably neutropenia (low white blood cell count), is common and dose-limiting. Febrile neutropenia (fever with low neutrophils) is a serious complication that requires immediate management.
Bowel Obstruction/Ileus: The drug is contraindicated in patients with pre-existing chronic inflammatory bowel disease or bowel obstruction due to increased risk.
Hypersensitivity: Severe allergic reactions, including anaphylaxis, have been reported.

Other Common Adverse Events

Adverse reactions reported in a majority of patients include hair loss (alopecia), nausea, vomiting, decreased appetite, fever, asthenia (weakness), and abdominal pain. Laboratory abnormalities such as leukopenia and anemia are also very common.

Population and Safety Notes

Hepatic Function: Patients with elevated bilirubin levels (up to 3 times the upper limit of normal) face a substantially increased risk of severe hematological toxicities, particularly in the first cycle. Use is contraindicated when bilirubin exceeds 3 times the upper limit of normal.
Elderly Patients: Patients 65 years of age and older require close monitoring due to a potentially higher risk of early-onset diarrhea and other toxicities.
Contraception: Use of effective contraception is recommended for patients of reproductive potential during treatment and for a specified period after the final dose.

Overdose and Emergency Response

Overdose and when to seek help

Overdose with Campto (Irinotecan) is defined in regulatory documents as an exaggeration of the known dose-limiting toxicities, requiring prompt and specific medical intervention.

Documented Overdose Presentations

The most serious manifestations listed in official prescribing information are Severe Diarrhea and Severe Myelosuppression.

Overdose Presentation	Associated Risks (Regulatory Terms)
Late-Onset Severe Diarrhea	Can be life-threatening; leads to dehydration, electrolyte imbalance, and potential sepsis.
Severe Myelosuppression	Grade 3 or 4 neutropenia (low white blood cell count), leukopenia, and thrombocytopenia.
Acute Cholinergic Syndrome	Transient symptoms like increased salivation, rhinitis, and sweating, often occurring during or shortly after infusion.

Other serious outcomes include rare cases of Acute Renal Failure (secondary to volume depletion) and Severe Hypersensitivity reactions, including anaphylaxis.

When Immediate Medical Help is Required

Official regulatory documents mandate seeking immediate medical attention or hospitalization under specific conditions:

Life-threatening symptoms such as signs of a severe allergic reaction or severe respiratory distress.
Hospitalization is recommended for diarrhea associated with fever, severe dehydration requiring intravenous fluid replacement, or diarrhea persisting for over 48 hours despite initial supportive management.

Management and Special Considerations

No specific antidote is known for Campto overdose; therefore, management focuses on intensive symptomatic and supportive treatment, including the use of Atropine for the acute cholinergic syndrome. Regulatory labeling specifically notes that individuals *homozygous for the UGT1A128 allele or those with elevated baseline serum total bilirubin** are at an increased risk for severe hematological toxicity.

Therapeutic Uses of Campto

Main Uses of Campto

Campto is a chemotherapy medication primarily used in the treatment of advanced colorectal cancer. It is specifically designed to address malignancies of the colon or rectum that have progressed or spread beyond the original site.

Treatment Settings

The application of this medication typically falls into two categories based on previous treatment history:

First-line therapy: It is used as an initial treatment for metastatic colorectal cancer, often administered in combination with other chemotherapy agents such as 5-fluorouracil and folinic acid.
Second-line therapy: It is used as a single-agent treatment for patients whose cancer has returned or progressed after an initial treatment regimen containing 5-fluorouracil.

How it Works

The active ingredient in Campto works by interfering with the enzyme topoisomerase I. This enzyme is responsible for managing the structure of DNA during the process of cell replication. By blocking this enzyme, the medication causes damage to the genetic material of cancer cells, preventing them from dividing and leading to their eventual destruction.

Therapeutic Benefits

The primary goal of treatment with Campto is to manage the progression of oncological disease. Potential benefits observed in clinical settings include:

Tumor Reduction: Shrinkage of existing metastatic lesions or primary tumors.
Disease Stabilization: Slowing or halting the growth of cancer cells for a period of time.
Progression-Free Survival: Increasing the duration of time during which the disease does not worsen.
Overall Survival Extension: Improving life expectancy in patients with advanced colorectal malignancies compared to other supportive care or previous standard treatments.

Regulatory References

National Cancer Institute overview of Irinotecan

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Campto (Irinotecan)

This profile summarizes the official population eligibility and non-eligibility information as defined by governmental regulatory documents (e.g., FDA, EMA).

Eligibility Scope

Category	Regulatory Status / Statement
Populations for whom use is allowed	Adult patients with metastatic carcinoma of the colon or rectum.
Populations for whom use is not recommended	Patients with impaired renal function (use not established); patients with WHO Performance Status 2.
Populations for whom use is contraindicated	Severe hypersensitivity, Chronic Inflammatory Bowel Disease/Bowel Obstruction, severe bone marrow failure, or total bilirubin levels mathbf> 3 times the Upper Limit of Normal (ULN).

Age-Related and Physiological Eligibility Rules

Category	Regulatory Status / Statement
Age-related eligibility rules	Safety and efficacy have not been established in pediatric patients. Patients mathbfgeq 65 years require close monitoring.
Condition-specific eligibility rules	Hepatic Impairment: Patients with bilirubin mathbf1.5 to mathbf3 times ULN require close monitoring. Do not use in patients on dialysis. Individuals with specific UGT1A1 alleles require special consideration.
Pregnancy and lactation eligibility status	Lactation is contraindicated. Females of reproductive potential must use effective contraception during and after treatment.

Connection to the overall eligibility profile

Regulatory documents define eligibility by establishing absolute prohibitions against use in patients with severe pre-existing physical or metabolic conditions (e.g., severe hepatic dysfunction or bowel obstruction) and certain concurrent treatments (e.g., St. John's Wort). Use is further governed by conditional restrictions related to age, genetic factors, and organ function, all of which mandate specific consideration before the medicine can be administered.

What should I know about interactions with other medicines?

Campto (irinotecan) is metabolized primarily by the CYP3A4 enzyme and detoxified mainly by the UGT1A1 enzyme. Therefore, it has significant interactions with medicines that affect these enzymes. Concurrent use may alter the concentration of the active drug metabolite, SN-38, leading to changes in efficacy or toxicity.

Important Drug Interactions

Type of Interaction	Examples of Interacting Medicines	Potential Outcome
Strong CYP3A4 Inducers	Phenytoin, Carbamazepine, Phenobarbital, Rifampicin, Rifabutin, St. John's Wort	Decreased SN-38 levels, potentially reducing Campto’s anti-tumor effect.
Strong CYP3A4 Inhibitors	Ketoconazole, Itraconazole, Atazanavir, Ritonavir, Clarithromycin	Increased SN-38 levels, potentially increasing the risk of severe toxicity (e.g., diarrhea, neutropenia).
UGT1A1 Inhibitors	Regorafenib, Pazopanib	Increased SN-38 levels, raising the risk of toxicity.
Vaccines	Live attenuated vaccines (e.g., Yellow Fever, Measles, Mumps, Rubella)	Increased risk of serious or fatal infection due to immunosuppression from Campto.

Patients must inform their healthcare providers about all medicines, over-the-counter products, and herbal supplements they are taking, as some, like St. John’s Wort, can severely impact Campto’s effectiveness. Dose adjustments or alternative therapies may be necessary to manage these interactions safely.

Mechanism of Action

The mechanism of action for Campto (Irinotecan) is defined by its highly specific molecular interference with DNA Topoisomerase I (Topo I), an enzyme essential for cellular life and division. The drug's key action is contingent upon its metabolic activation to SN-38, the active metabolite that executes the core pharmacodynamic mechanism.

Targeting Genomic Integrity via Enzyme Poisoning

This mechanism centers on the unique molecular interaction where SN-38 acts as a catalytic poison to Topo I, trapping the enzyme on the DNA strand in a complex. This action disrupts the fundamental pathway for regulating DNA structure. This enzyme trapping is the required trigger for the subsequent activation of programmed cellular destruction.

Cascade: S-Phase Dependent Cellular Termination

The resulting physiological consequence occurs only during the cell's S-Phase (DNA replication). When the cellular machinery attempts to copy the DNA, it collides with the trapped Topo I-drug complex, forcibly converting a minor DNA break into an irreversible double-strand DNA break. This irreparable genetic damage activates the apoptosis signaling cascade, resulting in the termination of highly proliferative cells.

Functional Selectivity and Mechanistic Constraints

The cytotoxic effect exhibits functional selectivity because it strictly requires the high activity levels of the DNA replication pathway, establishing a constraint against non-dividing cells (G0 phase). Furthermore, the mechanism can be limited by cellular defenses, such as efflux pump proteins, which actively reduce the concentration of the active SN-38 metabolite within the target cell.

Dosage and Administration Information

Administration and Dosing of Campto

Campto is a medicine strictly administered by Intravenous (IV) infusion only in a specialized healthcare setting. The medication must be diluted by a healthcare professional prior to infusion. It is not taken by mouth.

Official Administration Protocol

All doses must be delivered as a slow IV infusion over a 30- to 90-minute period. This specific administration time is a mandatory part of the official procedural guidelines.

Regimen	Dose	Schedule
Single-Agent	350 mg/m^2	Once every 3 weeks
Combination	180 mg/m^2	Once every 2 weeks

Preparation Requirements

Campto must be diluted for infusion in 500 mL of either 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection, USP, and thoroughly mixed by inversion before administration.

Dose Modification

The treatment protocol requires mandatory dose adjustment (reduction or delay) for subsequent cycles based on the patient’s experience in the previous cycle, particularly due to the severity of side effects such as low blood counts or diarrhea. A new cycle of therapy should not begin until certain treatment-related toxicities have recovered to defined levels, structuring the ongoing use of the drug. A lower starting dose may also be considered for patients who are 70 years of age or older when receiving the once-every-three-week schedule.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Campto (Irinotecan)

The research base for Irinotecan includes data from multiple studies, primarily built upon multi-center Randomized Controlled Trials (RCTs) and comprehensive meta-analyses. This evidence describes the clinical evaluation of the medicine across different patient settings, focusing on specific measured outcomes such as time until disease changes.

Evidence for Metastatic Colorectal Cancer (mCRC)

The research for the use of Irinotecan in advanced or metastatic carcinoma of the colon and rectum includes large-scale RCTs that compared Irinotecan-containing regimens against control treatments. The studies monitored outcomes like Overall Survival (OS) and Progression-Free Survival (PFS)—which measures the time until the cancer shows signs of progressing. Findings from these trials described patterns of measured OS and PFS in the study populations, both in previously treated patients and those receiving first-line treatment. These findings contribute to the broader evidence landscape that has been submitted for regulatory review. What remains uncertain involves the specific outcomes across all possible combination regimens, and findings were mixed when Irinotecan was studied for Stage III colon cancer (an earlier stage).

Evidence in Other Advanced Solid Tumors

Irinotecan was studied for its use in other aggressive cancers, including pancreatic, gastric, and lung tumors. Research often began with smaller Phase I and II studies designed to identify the appropriate administration dose. For metastatic pancreatic adenocarcinoma, RCTs were conducted for a specialized formulation of Irinotecan. Findings in these trials described patterns of measured OS and PFS in the Irinotecan formulation group, compared to a control regimen.

Studies in Specific Patient Groups

Research has explored the outcomes observed with Irinotecan in certain special populations, including older adults and pediatric patients. For children, small Phase I and II studies have been conducted. Research examined various administration schedules to document the observations in the study populations. Furthermore, research describes that an individual's genetic makeup, specifically variations in the UGT1A1 gene, was associated with differences in the body's exposure to the active form of the medicine, a factor that is monitored in some study populations.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Campto (FAQ)

Q: Is Campto used for other cancers besides the main ones listed?

A: Official regulatory documents indicate that Campto is specifically intended for the treatment of advanced or metastatic carcinoma of the colon or rectum. While the medicine has been studied in other tumors, such as lung or pancreatic cancers, its official regulatory indication remains disease-specific. Information regarding the appropriate use of Campto should be confirmed by a healthcare provider.

Q: Does Campto work better when combined with other medicines?

A: Official documentation defines specific dosing regimens for both use alone (single agent) and for use in combination with other medicines. The use of Campto in combination regimens is a standard approach described in the official regulatory indications for treatment. The choice of regimen depends on the patient's specific health situation and is determined by a healthcare professional.

Q: How long do side effects from Campto typically last after a cycle?

A: Official documents classify the timing of severe diarrhea, a major possible side effect, into two categories. Early-onset occurs within the first 24 hours of infusion, while late-onset typically occurs more than 24 hours after infusion. This time frame is an important part of how healthcare providers manage the risk of this side effect.

Q: Are there any common over-the-counter pain relievers that interact with Campto?

A: Regulatory-compliant patient information indicates that oversight by a healthcare provider is necessary before taking over-the-counter pain relievers. Medicines like ibuprofen or acetaminophen may interact with Campto or could potentially increase side effects, such as effects on the liver. Your healthcare provider can confirm which non-prescription medicines are safe to use.

Q: What kind of monitoring does a patient need while taking Campto?

A: The official protocol requires mandatory dose adjustments based on how a patient responds to the treatment, particularly concerning low blood counts or severe diarrhea. For this reason, patients require close and continuous monitoring by their healthcare team. This careful attention is especially important for certain groups, such as elderly patients or those with pre-existing conditions like elevated bilirubin levels.

Q: Can Campto cause long-term side effects that appear years later?

A: Official information indicates that some effects of irinotecan (the active ingredient in Campto) may still be observed after the medicine has been discontinued. However, patient information provided by regulatory bodies does not explicitly quantify or guarantee the appearance of side effects years later. All concerns regarding potential long-term effects should be discussed with the treatment team.

Q: What happens if I miss a scheduled treatment of Campto?

A: The official protocol requires consultation with the healthcare team immediately if a scheduled treatment is missed or anticipated to be missed. Adjustments to the treatment schedule, including managing a missed dose, must be handled and directed exclusively by the healthcare provider. The decision to stop or pause treatment is a medical decision that is managed under medical supervision.

Q: Are there specific food or drink items to avoid while receiving Campto?

A: Official patient information advises patients to avoid certain food and herbal items due to potential interactions. Specifically, grapefruit, grapefruit juice, starfruit, and Seville oranges should be avoided. These items can increase the concentration of the medicine in the blood, which may raise the risk of adverse effects.

Q: Can patients with pre-existing heart conditions use Campto?

A: Official patient information advises patients to inform their healthcare team about any significant medical history or pre-existing conditions. While specific contraindications are primarily focused on severe hepatic, renal, or bowel disease, informing the healthcare team about all conditions, including heart problems, allows for appropriate treatment planning.

Q: How is the decision made on how many cycles of Campto I will receive?

A: The total number of Campto cycles is determined as part of a specific treatment protocol. According to official documents, treatment cycles are typically scheduled every two or three weeks. The overall duration of treatment is guided by the patient’s specific disease status and the management of side effects.

Q: Does Campto interact with blood thinning medications?

A: Regulatory-compliant patient information indicates that discussion with a doctor is necessary before taking blood thinning medications like warfarin or aspirin. Because Campto can cause myelosuppression (low blood counts), it may lower the platelet count and increase a person’s risk of bleeding. This combination requires medical oversight.

Q: Can I drive after receiving a Campto treatment?

A: Official patient information indicates that Campto may cause dizziness or affect vision, particularly during the first 24 hours following the infusion. Therefore, official safety information indicates that operating a vehicle or complex machinery should be avoided until the patient understands the medicine's effect.

Q: Is there a generic version of Campto available?

A: Yes, the medicine's active ingredient, irinotecan hydrochloride, is available in generic form. Regulatory bodies, such as the FDA, have approved generic versions of the injection from various manufacturers.

Q: Why is hydration often emphasized for patients receiving Campto?

A: Hydration is emphasized because severe diarrhea is a serious and major side effect associated with Campto treatment. This severe diarrhea can potentially lead to life-threatening complications, including significant dehydration and electrolyte imbalance.

Q: Can Campto treatment be stopped abruptly, or does it need to be tapered?

A: Official patient guidance indicates that treatment cessation or interruption is a medical decision that is managed exclusively by the healthcare team. Patients should discuss their treatment plan with their healthcare provider before stopping the medicine for any reason.

Q: What parts of the body are most affected by Campto?

A: According to regulatory documents, the most common and serious adverse reactions are seen in the gastrointestinal and hematological systems. This includes effects on the stomach and intestines, and effects on the blood and bone marrow.

Q: What should I do if I experience severe diarrhea after receiving Campto?

A: Official safety information identifies severe diarrhea as a major dose-limiting toxicity that can be life-threatening. For this reason, the official safety protocol requires immediate consultation with a healthcare provider if severe diarrhea occurs after the treatment.

Q: What are the official regulatory approvals for Campto in my country?

A: Regulatory approval for Campto is country-specific and granted by the local governmental agency, such as the FDA, EMA, Health Canada, or TGA. The official indication approved by these bodies is for the treatment of advanced or metastatic colorectal cancer in specific regimens.

Q: Is Campto considered an immunosuppressant?

A: Campto is associated with myelosuppression, which is severe bone marrow suppression. This effect results in low white blood cell counts (neutropenia), lowering the body’s ability to fight infection. This risk factor is why regulatory documents specifically note the risk of serious infection when co-administering live attenuated vaccines.

Q: Why do some sources refer to Campto by a different name?

A: Campto is a common brand name for this medication. The medicine is also often referred to by its active ingredient, irinotecan hydrochloride, or by other brand names used globally, such as Camptosar.

Q: Are there any dietary restrictions that might make Campto less effective?

A: Official patient information advises avoiding certain foods and beverages due to the risk of interactions. For example, grapefruit products can increase the concentration of the active medicine in the body. Additionally, during treatment, you may be advised to limit foods or drinks that could worsen side effects like diarrhea.

Q: Is it true that Campto can cause vision changes?

A: Yes, official patient information indicates that the active ingredient, irinotecan, may affect vision. This side effect is specifically noted to occur, particularly during the first 24 hours after the medicine is administered.

Q: What is the purpose of pre-medication given before Campto infusion?

A: Pre-medication is recommended to manage certain potential side effects of the infusion. This typically includes antiemetic agents to help prevent nausea and vomiting. Additionally, a medicine called atropine may be considered to manage acute cholinergic symptoms like early-onset diarrhea, sweating, or flushing that can occur during the infusion.

Q: What information should I have ready for my healthcare provider before starting Campto?

A: Regulatory guidance details the patient information that is required for discussion with the healthcare provider prior to starting treatment. This includes all prescription and nonprescription medicines, vitamins, and herbal supplements you are currently taking. You should also discuss your full medical history, specifically focusing on any pre-existing conditions such as liver, kidney, or bowel problems.

How should Campto be stored and disposed of?

Storage and Disposal Requirements for Campto (Irinotecan)

The unopened Campto concentrate must be stored at Controlled Room Temperature, specifically between 15 C to 30 C (59 F to 86 F). The vial must remain in its original outer carton to ensure protection from light and must be kept out of the sight and reach of children.

Stability and Handling

Once the product is diluted for infusion, the solution is stable for up to 24 hours at room temperature or up to 48 hours under refrigeration (2 C to 8 C). As a cytotoxic agent, the product must be handled with caution and should be disposed of according to hospital standard procedures applicable to cytotoxic agents. Unused product and related materials must not be discarded in household waste or wastewater.

Campto